Physician profile
Daniel Yadegar
NPI 1538363213
$529.23
in general payments reported to CMS, 2019-2025
6 companies · $56.70 in 2025
The $56.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $137 · 2023: $30.47 · 2024: $74.80 · 2025: $56.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $255.14 | 2019-2024 | Euflexxa |
| Nevro Corp. | $137.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $56.70 | 2025 | |
| Stimwave Technologies Incorporated | $50.00 | 2019 | |
| Lilly USA, LLC | $30.36 | 2024 | Kisunla |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$600,033.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yadegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.